参考文献/References:
[1]Tanaka A,Hiramatsu E,Watanabe Y,et al.Efficacy of Long-Term Treatment With Tolvaptan to Prolong the Time Until Dialysis Initiation in Patients With Chronic Kidney Disease and Heart Failure[J].Ther Apher Dial,2019,23(4):319-327. [2]Imamura T.Patient Selection for Tolvaptan Therapy Among Those With Chronic Kidney Disease and Heart Failure[J].Ther Apher Dial,2020,24(1):96. [3]Torres VE.Vasopressin receptor antagonists,heart failure,and polycystic kidney disease[J].Annu Rev Med,2015(66):195-210. [4]齐菲,张士红.选择性AVP受体拮抗剂托伐普坦的药理及应用评价[J].医学与哲学,2016,37(2B):63-66. [5]Ronco C,Bellasi A,Di Lullo L.Cardiorenal Syndrome:An Overview[J].Adv Chronic Kidney Dis,2018,25(5):382-390. [6]Vinod P,Krishnappa V,Chauvin AM,et al.Cardiorenal Syndrome:Role of Arginine Vasopressin and Vaptans in Heart Failure[J].Cardiol Res,2017,8(3):87-95. [7]季瑞芬,边瓯,马宁,等.低剂量托伐普坦在2型心肾综合征合并低钠血症超高龄老年患者中应用近期临床评价[J].临床军医杂志,2016,44(2):169-172. [8]杨文,边瓯,马宁,等.托伐普坦联合呋塞米治疗超高龄Ⅰ型心肾综合征患者6例[J].中国新药与临床杂志,2015,34(6):479-483. [9]Katsumata M,Hirawa N,Sumida K,et al.Effects of tolvaptan in patients with chronic kidney disease and chronic heart failure[J].Clin Exp Nephrol,2017,21(5):858-865. [10]Tominaga N,Kida K,Inomata T,et al.Effects of Tolvaptan Addition to Furosemide in Normo-and Hyponatremia Patients with Heart Failure and Chronic Kidney Disease Stages G3b-5:A Subanalysis of the K-STAR Study[J].Am J Nephrol,2017,46(5):417-426. [11]Verbalis JG,Goldsmith SR,Greenberg A,et al.Diagnosis,evaluation,and treatment of hyponatremia:expert panel recommendations[J].Am J Med,2013,126(10 Suppl 1):S1-S42. [12]徐小元,丁惠国,李文刚,等.肝硬化腹水及相关并发症的诊疗指南[J].传染病信息,2017,30(5):237-253. [13]朴莲淑.托伐普坦联合白蛋白治疗肝硬化合并2型肝肾综合征的疗效观察[J].中国医药指南,2015,13(25):150. [14]叶楠,程虹,谌贻璞,等.托伐普坦治疗肾病综合征患者水肿的疗效与安全性[J].中华肾脏病杂志,2018,34(4):274-280. [15]Park ES,Huh YS,Kim GH.Is tolvaptan indicated for refractory oedema in nephrotic syndrome[J].Nephrology(Carlton),2015,20(2):103-106. [16]Shimizu M,Ishikawa S,Yachi Y,et al.Tolvaptan therapy for massive edema in a patient with nephrotic syndrome[J].Pediatr Nephrol,2014,29(5):915-917. [17]Tanaka A,Nakamura T,Sato E,et al.Different Effects of Tolvaptan in Patients with Idiopathic Membranous Nephropathy with Nephrotic Syndrome[J].Intern Med,2017,56(2):191-196. [18]Masuda T,Ohara K,Nagayama I,et al.Impact of serum albumin levels on the body fluid response to tolvaptan in chronic kidney disease patients[J].Int Urol Nephrol,2019,51(9):1623-1629. [19]Kinugawa K,Sato N,Inomata T,et al.Efficacy and safety of tolvaptan in heart failure patients with volume overload[J].Circ J,2014,78(4):844-852. [20]Inomata T,Ikeda Y,Kida K,et al.Effects of Additive Tolvaptan vs. Increased Furosemide on Heart Failure With Diuretic Resistance and Renal Impairment -Results From the K-STAR Study[J].Circ J, 2017,82(1):159-167. [21]Hines Cheryl B,Hooper Gwendolyn L,Collins-Yoder Angela.Tolvaptan for Autosomal Dominant Polycystic Kidney Disease:Pharmacokinetics and Implications for Practice[J].Nephrol Nurs J,2020,47(2):145-150. [22]Torres VE,Chapman AB,Devuyst O,et al.Tolvaptan in patients with autosomal dominant polycystic kidney disease[J].N Engl J Med,2013,367(25):2407-2418. [23]Torres VE,Chapman AB,Devuyst O,et al.Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease[J].N Engl J Med,2017,377(20):1930-1942. [24]Casteleijn NF,Blais JD,Chapman AB,et al.Tolvaptan and Kidney Pain in Patients With Autosomal Dominant Polycystic Kidney Disease:Secondary Analysis From a Randomized Controlled Trial[J].Am J Kidney Dis,2017,69(2):210-219. [25]Blair HA.Tolvaptan:A Review in Autosomal Dominant Polycystic Kidney Disease[J].Drugs,2019,79(3):303-313. [26]Lee WC,Fang HY,Fang CY.Tolvaptan rescue contrast-induced acute kidney injury:A case report[J].Medicine(Baltimore),2018,97(17):570. [27]Yamashita K,Igawa W,Ono M,et al.Safety and Efficacy of Tolvaptan for the Prevention of Contrast-Induced Acute Kidney Injury in Patients with Heart Failure and Chronic Kidney Disease[J].Kidney Dis(Basel),2019,5(2):100-106.